Fig. 1

γδ T cell subsets in PBMCs of donors before and after G-CSF treatment in vivo. a, b CD27 and CD25 expression in γδTregs, Vδ1Tregs and Vδ2Tregs in PBMCs from 30 donors before (a) and after (b) G-CSF treatment in vivo (the figures are representative of one case). c Percentages of total γδ T cells, Vδ1 T cells, Vδ2 T cells, γδTregs, Vδ1Tregs and Vδ2Tregs in PBMCs of 30 donors before and after G-CSF treatment in vivo. d Percentages of CD27⁺γδTregs, CD27⁺Vδ1Tregs, CD27⁺Vδ2Tregs, CD25⁺γδTregs, CD25⁺Vδ1Tregs and CD25⁺Vδ2Tregs in PBMCs of 30 donors before and after G-CSF treatment in vivo. *P < 0.05